KOKOWA
2021-08-27
👍
Why Zomedica Stock Is Zooming Higher Today<blockquote>为什么Zomedica股票今天飙升</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
4
6
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":819310400,"tweetId":"819310400","gmtCreate":1630033330200,"gmtModify":1704954926874,"author":{"id":3557704604168397,"idStr":"3557704604168397","authorId":3557704604168397,"authorIdStr":"3557704604168397","name":"KOKOWA","avatar":"https://static.tigerbbs.com/eeff56eeb7ebce5a55608cef0cd0bfae","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":13,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":187,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>👍</p></body></html>","htmlText":"<html><head></head><body><p>👍</p></body></html>","text":"👍","highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":4,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/819310400","repostId":1122548190,"repostType":4,"repost":{"id":"1122548190","kind":"news","pubTimestamp":1630031791,"share":"https://www.laohu8.com/m/news/1122548190?lang=zh_CN&edition=full","pubTime":"2021-08-27 10:36","market":"us","language":"en","title":"Why Zomedica Stock Is Zooming Higher Today<blockquote>为什么Zomedica股票今天飙升</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1122548190","media":"Motley Fool","summary":"Key Points\n\nThere wasn't any news from Zomedica to serve as a catalyst.\nToday's gain appears to be c","content":"<p>Key Points</p><p><blockquote>要点</blockquote></p><p> <ul> <li>There wasn't any news from Zomedica to serve as a catalyst.</li> <li>Today's gain appears to be continued momentum related to an SEC filing made earlier this week by Morgan Stanley.</li> </ul> What happened</p><p><blockquote><ul><li>Zomedica没有任何消息可以起到催化剂的作用。</li><li>今天的上涨似乎是与摩根士丹利本周早些时候向美国证券交易委员会提交的文件相关的持续势头。</li></ul>发生了什么</blockquote></p><p> Shares of <b>Zomedica</b>(NYSEMKT:ZOM)were zooming 16.7% higher as of 11:40 a.m. EDT on Thursday after soaring as much as 37.9% earlier in the session. There wasn't any news from the company, though.</p><p><blockquote>本公司之股份<b>佐梅迪卡</b>截至美国东部时间周四上午11点40分，(NYSEMKT：ZOM)股价上涨16.7%，此前盘中曾飙升37.9%。不过，公司没有任何消息。</blockquote></p><p> Instead, today's big gain appears to be a continuation of momentum from earlier this week following a filing<b>Morgan Stanley</b>(NYSE:MS)made with the U.S. Securities and Exchange Commission. That SEC filing revealed that Morgan Stanley had invested more than $1.6 million in Zomedica stock.</p><p><blockquote>相反，今天的大幅上涨似乎是本周早些时候提交文件后势头的延续<b>摩根士丹利</b>（纽约证券交易所代码：MS）与美国证券交易委员会达成。该SEC文件显示，摩根士丹利已向Zomedica股票投资了超过160万美元。</blockquote></p><p> So what</p><p><blockquote>那又怎样</blockquote></p><p> It's good news that a major investment bank thinks highly enough of Zomedica that it's buying the animalhealthcare stock. However, some context might be helpful. Morgan Stanley bought a little under 2 million shares. That's barely 0.2% of Zomedica's outstanding shares.</p><p><blockquote>好消息是，一家大型投资银行对Zomedica的评价足够高，因此购买了动物保健股票。然而，一些背景可能会有所帮助。摩根士丹利购买了略低于200万股。这仅占Zomedica流通股的0.2%。</blockquote></p><p> Buying Zomedica just because Morgan Stanley did isn't a prudent move. On the other hand, investing because the business fundamentals could improve significantly in the future can be a good reason to buy a stock.</p><p><blockquote>仅仅因为摩根士丹利买入Zomedica并不是一个谨慎的举动。另一方面，因为业务基本面在未来可能会显着改善而进行投资可能是购买股票的一个很好的理由。</blockquote></p><p> In this case, there are reasons to think that Zomedica's business could pick up relatively soon. The big question for investors, though, is whether sales will increase enough to justify the company's market cap of close to $500 million.</p><p><blockquote>在这种情况下，有理由认为Zomedica的业务可能会相对较快地回升。不过，投资者面临的一个大问题是，销售额是否会增长到足以证明该公司近5亿美元的市值是合理的。</blockquote></p><p> Now what</p><p><blockquote>现在怎么办</blockquote></p><p> Zomedica expects that its fT4 assay for veterinarians to diagnose potential thyroid problems in animals will be available this fall. The company hopes its ACTH assay for testing animals' cortisol levels will be on the market by the end of the year. The rollouts of these assays could boost sales for Zomedica's Truforma diagnostic instruments.</p><p><blockquote>Zomedica预计，其用于兽医诊断动物潜在甲状腺问题的fT4检测将于今年秋天上市。该公司希望其用于测试动物皮质醇水平的ACTH检测方法能够在今年年底上市。这些检测方法的推出可能会促进Zomedica Truforma诊断仪器的销售。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Zomedica Stock Is Zooming Higher Today<blockquote>为什么Zomedica股票今天飙升</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Zomedica Stock Is Zooming Higher Today<blockquote>为什么Zomedica股票今天飙升</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-08-27 10:36</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Key Points</p><p><blockquote>要点</blockquote></p><p> <ul> <li>There wasn't any news from Zomedica to serve as a catalyst.</li> <li>Today's gain appears to be continued momentum related to an SEC filing made earlier this week by Morgan Stanley.</li> </ul> What happened</p><p><blockquote><ul><li>Zomedica没有任何消息可以起到催化剂的作用。</li><li>今天的上涨似乎是与摩根士丹利本周早些时候向美国证券交易委员会提交的文件相关的持续势头。</li></ul>发生了什么</blockquote></p><p> Shares of <b>Zomedica</b>(NYSEMKT:ZOM)were zooming 16.7% higher as of 11:40 a.m. EDT on Thursday after soaring as much as 37.9% earlier in the session. There wasn't any news from the company, though.</p><p><blockquote>本公司之股份<b>佐梅迪卡</b>截至美国东部时间周四上午11点40分，(NYSEMKT：ZOM)股价上涨16.7%，此前盘中曾飙升37.9%。不过，公司没有任何消息。</blockquote></p><p> Instead, today's big gain appears to be a continuation of momentum from earlier this week following a filing<b>Morgan Stanley</b>(NYSE:MS)made with the U.S. Securities and Exchange Commission. That SEC filing revealed that Morgan Stanley had invested more than $1.6 million in Zomedica stock.</p><p><blockquote>相反，今天的大幅上涨似乎是本周早些时候提交文件后势头的延续<b>摩根士丹利</b>（纽约证券交易所代码：MS）与美国证券交易委员会达成。该SEC文件显示，摩根士丹利已向Zomedica股票投资了超过160万美元。</blockquote></p><p> So what</p><p><blockquote>那又怎样</blockquote></p><p> It's good news that a major investment bank thinks highly enough of Zomedica that it's buying the animalhealthcare stock. However, some context might be helpful. Morgan Stanley bought a little under 2 million shares. That's barely 0.2% of Zomedica's outstanding shares.</p><p><blockquote>好消息是，一家大型投资银行对Zomedica的评价足够高，因此购买了动物保健股票。然而，一些背景可能会有所帮助。摩根士丹利购买了略低于200万股。这仅占Zomedica流通股的0.2%。</blockquote></p><p> Buying Zomedica just because Morgan Stanley did isn't a prudent move. On the other hand, investing because the business fundamentals could improve significantly in the future can be a good reason to buy a stock.</p><p><blockquote>仅仅因为摩根士丹利买入Zomedica并不是一个谨慎的举动。另一方面，因为业务基本面在未来可能会显着改善而进行投资可能是购买股票的一个很好的理由。</blockquote></p><p> In this case, there are reasons to think that Zomedica's business could pick up relatively soon. The big question for investors, though, is whether sales will increase enough to justify the company's market cap of close to $500 million.</p><p><blockquote>在这种情况下，有理由认为Zomedica的业务可能会相对较快地回升。不过，投资者面临的一个大问题是，销售额是否会增长到足以证明该公司近5亿美元的市值是合理的。</blockquote></p><p> Now what</p><p><blockquote>现在怎么办</blockquote></p><p> Zomedica expects that its fT4 assay for veterinarians to diagnose potential thyroid problems in animals will be available this fall. The company hopes its ACTH assay for testing animals' cortisol levels will be on the market by the end of the year. The rollouts of these assays could boost sales for Zomedica's Truforma diagnostic instruments.</p><p><blockquote>Zomedica预计，其用于兽医诊断动物潜在甲状腺问题的fT4检测将于今年秋天上市。该公司希望其用于测试动物皮质醇水平的ACTH检测方法能够在今年年底上市。这些检测方法的推出可能会促进Zomedica Truforma诊断仪器的销售。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/08/26/why-zomedica-stock-is-zooming-higher-today/\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/08/26/why-zomedica-stock-is-zooming-higher-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122548190","content_text":"Key Points\n\nThere wasn't any news from Zomedica to serve as a catalyst.\nToday's gain appears to be continued momentum related to an SEC filing made earlier this week by Morgan Stanley.\n\nWhat happened\nShares of Zomedica(NYSEMKT:ZOM)were zooming 16.7% higher as of 11:40 a.m. EDT on Thursday after soaring as much as 37.9% earlier in the session. There wasn't any news from the company, though.\nInstead, today's big gain appears to be a continuation of momentum from earlier this week following a filingMorgan Stanley(NYSE:MS)made with the U.S. Securities and Exchange Commission. That SEC filing revealed that Morgan Stanley had invested more than $1.6 million in Zomedica stock.\nSo what\nIt's good news that a major investment bank thinks highly enough of Zomedica that it's buying the animalhealthcare stock. However, some context might be helpful. Morgan Stanley bought a little under 2 million shares. That's barely 0.2% of Zomedica's outstanding shares.\nBuying Zomedica just because Morgan Stanley did isn't a prudent move. On the other hand, investing because the business fundamentals could improve significantly in the future can be a good reason to buy a stock.\nIn this case, there are reasons to think that Zomedica's business could pick up relatively soon. The big question for investors, though, is whether sales will increase enough to justify the company's market cap of close to $500 million.\nNow what\nZomedica expects that its fT4 assay for veterinarians to diagnose potential thyroid problems in animals will be available this fall. The company hopes its ACTH assay for testing animals' cortisol levels will be on the market by the end of the year. The rollouts of these assays could boost sales for Zomedica's Truforma diagnostic instruments.","news_type":1,"symbols_score_info":{"ZOM":0.9}},"isVote":1,"tweetType":1,"viewCount":850,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":2,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/819310400"}
精彩评论